Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3323795 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Itraconazole (Primary) ; LY 3323795 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 05 Mar 2018 Status changed from recruiting to completed.
- 31 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
- 31 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.